Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-OPNc phosphothioate oligomer
- Development stage
- Preclinical
- Lead developer
- Instituto Nacional de Câncer
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
anti-OPNc phosphothioate oligomer is a phosphorothioate-modified antisense DNA oligonucleotide (ASO) designed to selectively knock down the expression of osteopontin-c (OPNc), a splice variant of osteopontin (SPP1). Developed by researchers at the National Cancer Institute (INCA) in Brazil, this oligomer is used as a preclinical research tool to investigate the role of OPNc in mediating chemoresistance, cell survival, and epithelial-mesenchymal transition (EMT) in various cancer models, including breast cancer, ovarian cancer, and B-cell acute lymphoblastic leukemia (B-ALL). By silencing OPNc, the oligomer downregulates P-glycoprotein (P-gp) expression and sensitizes drug-resistant cancer cells to chemotherapeutic agents such as doxorubicin and cisplatin.
- Other names
- anti-OPNc ASOanti-OPNc antisense oligonucleotideanti-OPNc phosphorothioate-modified antisense DNA oligomeranti-OPNc phosphorothiotate-modified antisense DNA oligomeranti-OPNc phosphothiotate-modified DNA oligomerASO anti-OPNc
02
Targets
SPP1 (Osteopontin)
Beyond the preview
Go deeper on anti-OPNc phosphothioate oligomer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-OPNc phosphothioate oligomer.